3,934 results match your criteria Imaging in Prostate Carcinoma


Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.

EJNMMI Res 2020 May 24;10(1):52. Epub 2020 May 24.

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.

Background: PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [F]FDG-avid lesions with low or no PSMA expression ([F]FDG/[Ga]Ga-PSMA-11 mismatch findings on PET/CT) in the course of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-020-00640-2DOI Listing

Folic acid-modified methotrexate-conjugated gold nanoparticles as nano-sized trojans for drug delivery to folate receptor-positive cancer cells.

Nanotechnology 2020 May 15. Epub 2020 May 15.

Department of Chemical Engineering, Istanbul University-Cerrahpasa, Istanbul, Istanbul, TURKEY.

Methotrexate (MTX), an analog of folic acid (FA), is a drug widely used in cancer treatment. To prevent its potential toxicity and enhance therapeutic efficacy, targeted drug delivery system, especially nanotechnology-folate platforms, is a central strategy. Gold nanoparticles (AuNPs) are promising candidates to be used as drug delivery systems because of their small particle sizes and their inertness for the body. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6528/ab9395DOI Listing

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.

Eur J Nucl Med Mol Imaging 2020 May 13. Epub 2020 May 13.

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Purpose: First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04777-zDOI Listing

Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends.

Cancers (Basel) 2020 May 11;12(5). Epub 2020 May 11.

Department of Radiology, University of California, Irvine, Orange, CA 92868-3201, USA.

Prostate carcinoma is one of the most prevalent cancers worldwide. Multiparametric magnetic resonance imaging (mpMRI) is a non-invasive tool that can improve prostate lesion detection, classification, and volume quantification. Machine learning (ML), a branch of artificial intelligence, can rapidly and accurately analyze mpMRI images. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051204DOI Listing

Contrast-enhanced ultrasound evaluation of the prostate before transrectal ultrasound-guided biopsy can improve diagnostic sensitivity: A STARD-compliant article.

Medicine (Baltimore) 2020 May;99(19):e19946

Department of Ultrasound, The First Affiliated Hospital of Hainan Medical University, No. 31, Longhua Road, Haikou 570102, China.

To conduct a STARD-compliant validity that the contrast-enhanced ultrasound (CEUS) evaluation of prostate for the improvement of positive rate of biopsy and diagnostic efficiency of prostate carcinoma (PCa).Data of 137 patients with suspected PCa who underwent relevant examinations and treatment were reviewed, and 82 of 137 patients were finally included. The patients consisted of Group 1 (26 patients) and Group 2 (42 patients) according to which they underwent transrectal ultrasound (TRUS) biopsy selected from CEUS evaluation of the prostate and who underwent TRUS-guided biopsy directly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019946DOI Listing

Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines.

Cancer Cell Int 2020 29;20:139. Epub 2020 Apr 29.

1Division of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Ernst-Heydemann Str. 6, 18057 Rostock, Germany.

Background: Canine prostate cancer represents a unique model for human prostate cancer. In vitro systems offer various possibilities but Xenograft in vivo imaging allows studying complex tasks as tumor progression and drug intervention longitudinal. Herein, we established three canine prostate carcinoma cell lines stably expressing fluorescent proteins allowing deep tissue in vivo imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-020-01211-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189542PMC

Incremental Value of Ga-68 Prostate-Specific Membrane Antigen-11 Positron-Emission Tomography/Computed Tomography Scan for Preoperative Risk Stratification of Prostate Cancer.

Indian J Nucl Med 2020 Apr-Jun;35(2):93-99. Epub 2020 Mar 12.

Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon, Haryana, India.

Background: Prostate cancer (PC) is the second-most common cause of cancer.Ga-prostate-specific membrane antigen (PSMA)-11 positron-emission tomography/computed tomography (PET/CT) scan help in accurate staging of PC owing to its high PSMA avidity and specificity. The aim of this prospective observational study was to determine the incremental value of Ga-68 PSMA-11 PET/CT over multiparametric magnetic resonance imaging (mpMRI) in the locoregional staging of intermediate- and high-risk PC using histopathology from radical prostatectomy specimens as a gold standard. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijnm.IJNM_189_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182336PMC

Brightfield multiplex immunohistochemistry with multispectral imaging.

Lab Invest 2020 Apr 27. Epub 2020 Apr 27.

Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.

Brightfield microscopy is the preferred method of pathologists for diagnosing solid tumors, utilizing common staining techniques such as hematoxylin and eosin staining and immunohistochemistry (IHC). However, as our understanding of the complex tumor microenvironment grows, there is increasing demand for multiplexed biomarker detection. Currently, multiplexed IHC assays are almost exclusively based on immunofluorescence because brightfield techniques are limited by the broad spectral absorption of chromogens and a reliance on conventional 3-channel color cameras. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41374-020-0429-0DOI Listing

Transrectal Ultrasound Guided Prostatic Biopsy and its Complications: A Descriptive Cross-sectional Study.

Authors:
Robin Joshi

JNMA J Nepal Med Assoc 2020 Jan;58(221):44-47

Department of Urology, Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.

Introduction: Transrectal ultrasound of prostate provides better visual for biopsy. Transrectal ultrasound guided prostate biopsy is usually performed in men with an abnormal digital rectal examination, and elevated prostate specific antigen (>4ng/ml) or prostate specific antigen velocity (rate of prostate specific antigen change) i.e. Read More

View Article

Download full-text PDF

Source
January 2020

Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis.

Clin Nucl Med 2020 Jun;45(6):465-467

From the Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou.

A 51-year-old man with 30-year neurofibromatosis and 2-month elevated prostate-specific antigen and back pain underwent a Ga-prostate-specific membrane antigen (PSMA) PET/CT scan for possible prostate cancer. Prostate-specific membrane antigen PET/CT imaging showed no abnormal uptake of the prostate. However, in addition to PSMA uptake in his left lung, thorax, and right ilium, which was confirmed being a lung squamous cell carcinoma by a lung biopsy, widespread uptake was also observed in his skin fibroma lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003039DOI Listing
June 2020
3.931 Impact Factor

18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer.

Clin Nucl Med 2020 Jun;45(6):e276-e278

Kuwait Cancer Control Centre, Kuwait City, Kuwait.

A 72-year-old man, who is known with a case of metastatic carcinoma of the breast, was referred for F-PMSA 1007 PET/CT with clinical suspicion of synchronous prostate cancer. F-PSMA 1007 PET/CT scan detected no abnormal tracer concentrating lesion in the prostate gland; however, abnormal tracer concentration was noted in soft tissue lesions in left breast, metastatic lymph nodes, and skeletal lesions. Compared with F-FDG PET/CT, more bone lesions were detected on F-PSMA 1007 imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003013DOI Listing
June 2020
3.931 Impact Factor

Isolated Intravascular Prostate Carcinoma Recurrence Confirmed With 18F-Fluciclovine PET/CT and MRI.

Clin Nucl Med 2020 Jun;45(6):442-443

From the Department of Radiology, Mayo Clinic, Jacksonville.

Late recurrence of prostate cancer after remission with prior radical prostatectomy is uncommon. This is a unique case of biochemical recurrence after being in remission for 12 years. The patient presented with swelling of the right lower extremity with pelvic MRI demonstrating an arterially enhancing filling defect in the right common iliac. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003011DOI Listing

Bioresponsive Nanomedicine: The Next Step of Deadliest Cancers' Theranostics.

Front Chem 2020 9;8:257. Epub 2020 Apr 9.

Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.

Among all cancers, lung, breast, and prostate carcinoma are the three most fatal cancers. Although general therapeutic strategies and existent nanomedicine have been applied in relating cancer treatments, the side effects and potential damage induced by the off-target effect greatly lower the therapeutic efficiency. Recently, an increasing number of bioresponsive nanomaterials is recruited in fighting these deadliest cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fchem.2020.00257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161533PMC

[A Case of Neuroendcrine Carcinoma of the Prostate Diagnosed by Prostate Re-Biopsy during Hormonal Treatment and Effectively Treated by Multidisciplinary Therapy].

Hinyokika Kiyo 2020 Mar;66(3):91-96

The Department of Urology, Miyazaki University Hospital.

A 73-year-old Japanese man visited the urology clinic with the chief complaint of gross hematuria in June 2015. His prostate specific antigen (PSA) level was 146.7 ng/ml and he was diagnosed with prostate adenocarcinoma with a Gleason Score of 5+4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_66_3_91DOI Listing

Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.

BJU Int 2020 Apr 21. Epub 2020 Apr 21.

Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Objectives: To compare and evaluate a multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) strategy, contrast-ultrasound-dispersion imaging (CUDI)-TBx strategy and systematic biopsy (SBx) strategy for the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve men.

Patients And Methods: A prospective, single-centre paired diagnostic study included 150 biopsy-naïve men, from November 2015 to November 2018. All men underwent pre-biopsy mpMRI and CUDI followed by a 12-core SBx taken by an operator blinded from the imaging results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.15093DOI Listing

Diagnostic Performance of 68Gallium-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma.

Health Phys 2020 Apr 14. Epub 2020 Apr 14.

Clinic of Nuclear Medicine, Johannes Gutenberg-University, 55101 Mainz, Germany.

Gallium-68 (Ga) prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography is a highly promising method for imaging primary and recurrent prostate cancer. These dual-modality imaging technologies enable whole-body functional and anatomical evaluation in a single session. This study investigated the performance of Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HP.0000000000001253DOI Listing

PSMA expression on neovasculature of solid tumors.

Histol Histopathol 2020 Apr 13:18215. Epub 2020 Apr 13.

Department of Nuclear Medicine, AZ Groeninge, Kortrijk, Belgium.

The use of prostate specific membrane antigen (PSMA) binding agents, labelled with diagnostic and therapeutic radio-isotopes is opening the potential for a new era of personalized management of prostate carcinoma. A wide variety of immunohistochemistry studies have shown PSMA also to be upregulated on the endothelial cells of the neovasculature of a wide variety of other solid tumors where it may facilitate endothelial cell sprouting and invasion through its regulation of lytic proteases that have the ability to cleave the extracellular matrix. Similar to the introduction of PSMA-targeting theranostics in prostate carcinoma, overexpression of PSMA on newly formed tumor vessels may serve as a target for imaging and subsequent treatment of cancer through the use of agents that are capable of blocking PSMA in its function or through PSMA-mediated delivery of chemotherapeutics or radiation agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-18-215DOI Listing

Multilabel segmentation of cancer cell culture on vascular structures with deep neural networks.

J Med Imaging (Bellingham) 2020 Mar 7;7(2):024001. Epub 2020 Apr 7.

University of Jyväskylä, Faculty of Information Technology, Jyväskylä, Finland.

New increasingly complex cancer cell models are being developed. These new models seem to represent the cell behavior more accurately and have better physiological relevance than prior models. An efficient testing method for selecting the most optimal drug treatment does not exist to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1117/1.JMI.7.2.024001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138259PMC

[Stereotactic body radiotherapy (SBRT) for the treatment of bone metastases in oligometastasised prostate cancer].

Aktuelle Urol 2020 Apr 8. Epub 2020 Apr 8.

Klinikum rechts der Isar der Technischen Universität München, Klinik für RadioOnkologie und Strahlentherapie, München.

Background:  Local radiation therapy of metastases in prostate cancer patients has become increasingly important in recent years. In order to improve the evaluation of the outcome, we have studied oligometastatic prostate cancer patients who were treated with stereotactic radiation therapy.

Patients And Methods:  24 patients with a total of 30 bone metastases were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1140-5646DOI Listing

Imaging assessment of local recurrence of prostate cancer after radical prostatectomy.

Abdom Radiol (NY) 2020 Apr 4. Epub 2020 Apr 4.

Division of Abdominal Radiology, Department of Radiology, Mayo Clinic, 5777 E. Mayo Blvd, PX SS01 RADLGY, Phoenix, AZ, 85054, USA.

Definitive therapy for prostate cancer includes radical prostatectomy and radiation therapy. Treatment is elected based on patient preference, biological tumor factors, and underlying health. Post prostatectomy, men are surveyed for disease recurrence with serial PSA measurements, digital rectal exam, and imaging studies depending on nomogram predicted risk of local disease recurrence and distant metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02505-7DOI Listing

Tumor-penetrating peptide for systemic targeting of Tenascin-C.

Sci Rep 2020 Apr 2;10(1):5809. Epub 2020 Apr 2.

Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Extracellular matrix in solid tumors has emerged as a specific, stable, and abundant target for affinity-guided delivery of anticancer drugs. Here we describe the homing peptide that interacts with the C-isoform of Tenascin-C (TNC-C) upregulated in malignant tissues. TNC-C binding PL3 peptide (amino acid sequence: AGRGRLVR) was identified by in vitro biopanning on recombinant TNC-C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-62760-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118115PMC
April 2020
5.078 Impact Factor

Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?

BJU Int 2020 Mar 31. Epub 2020 Mar 31.

Departments of, Department of, Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Objectives: To investigate whether serial prostate magnetic resonance imaging (MRI) may guide the utility of repeat targeted (TBx) and systematic biopsy (SBx) when monitoring men with low-risk prostate cancer (PCa) at 1-year of active surveillance (AS).

Patients And Methods: We retrospectively included 111 consecutive men with low-risk (International Society of Urological Pathology [ISUP] Grade 1) PCa, who received protocolled repeat MRI with or without TBx and repeat SBx at 1-year of AS. TBx was performed in Prostate Imaging-Reporting and Data System (PI-RADS) score ≥3 lesions (MRI-positive men). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.15065DOI Listing

All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma.

Hell J Nucl Med 2020 Jan-Apr;23(1):79-80. Epub 2020 Mar 31.

Department of Nuclear Medicine and Molecular Imaging, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium.

We present a case of a 79 year old patient with a medical history of unilateral nerve-sparing radical prostatectomy due to a pT3aN0 (Gleason score 7) prostate carcinoma. Because of slightly elevated prostate specific antigen (PSA) level (0.35ng/dL), a fluorine-18-prostate specific membrane antigen (F-PSMA)-1007 positron emission tomography/computed tomography (PET/CT) scan was performed, showing no signs of malignant recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1967/s002449912007DOI Listing

[Pelvic MRI combined with TRUS-guided transperineal template mapping biopsy for the diagnosis of prostate cancer].

Zhonghua Nan Ke Xue 2019 May;25(5):408-413

Department of Urology, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu 215000, China.

Objective: To assess the clinical value and safety of pelvic MRI combined with transurethral ultrasound (TRUS)-guided transperineal template mapping biopsy (TTMB) in the diagnosis of prostate cancer.

Methods: A total of 164 men underwent MRI plus TRUS-guided TTMB for the diagnosis of prostate cancer from December 2015 to May 2018. The patients averaged 71. Read More

View Article

Download full-text PDF

Source

18F-PSMA 1007 in Suspected Renal Cell Carcinoma.

Clin Nucl Med 2020 May;45(5):377-378

From the Jaber Alahmad Centre for Molecular Imaging, Shuwaikh, Kuwait.

A 60-year-old man with suspected right renal cell carcinoma underwent F-FDG PET/CT and F prostate-specific membrane antigen (PSMA) 1007 PET/CT scan. Compared with the F-FDG PET/CT scan, F-PSMA 1007 PET/CT showed intense tracer concentration in the primary tumor in the right kidney and intense tracer concentration consistently in all lung nodules. Unlike noted in previous pilot studies with Ga-PSMA, we observed that the primary renal tumor also showed intense tracer avidity with F-PSMA 1007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003002DOI Listing
May 2020
3.931 Impact Factor

Development of Novel -In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Biomolecules 2020 Mar 19;10(3). Epub 2020 Mar 19.

Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, Rouen, France, 76000 Rouen, France.

Overexpression of G protein-coupled receptors (GPCRs) in tumours is widely used to develop GPCR-targeting radioligands for solid tumour imaging in the context of diagnosis and even treatment. The human vasoactive neuropeptide urotensin II (hUII), which shares structural analogies with somatostatin, interacts with a single high affinity GPCR named UT. High expression of UT has been reported in several types of human solid tumours from lung, gut, prostate, or breast, suggesting that UT is a valuable novel target to design radiolabelled hUII analogues for cancer diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom10030471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175314PMC

Pan-cancer diagnostic consensus through searching archival histopathology images using artificial intelligence.

NPJ Digit Med 2020 10;3:31. Epub 2020 Mar 10.

7Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA USA.

The emergence of digital pathology has opened new horizons for histopathology. Artificial intelligence (AI) algorithms are able to operate on digitized slides to assist pathologists with different tasks. Whereas AI-involving classification and segmentation methods have obvious benefits for image analysis, image search represents a fundamental shift in computational pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41746-020-0238-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064517PMC

Preparation and clinical translation of Tc-PSMA-11 for SPECT imaging of prostate cancer.

Medchemcomm 2019 Dec 22;10(12):2111-2117. Epub 2019 Nov 22.

Radiopharmaceuticals Division , India . Email: ; ; Tel: +91 22 25590748.

This study explores the feasibility of radiolabeling the HBED-CC-PSMA (PSMA-11) ligand with Tc-99m for SPECT imaging of prostate cancer patients. Ga-HBED-CC-PSMA (PSMA-11) is used clinically for PET/CT imaging of prostate cancer (PCa) patients. However, a PET/CT facility may not be affordable and/or accessible to remotely located health centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c9md00401gDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067243PMC
December 2019
2.495 Impact Factor

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [Ga]PSMA-PET-guided metastasis-directed therapy.

Eur J Nucl Med Mol Imaging 2020 Mar 16. Epub 2020 Mar 16.

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Strasse 22, 81675, Munich, Germany.

Purpose: Since the success of prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging for patients with oligorecurrent prostate cancer (ORPC), it is increasingly used for radiotherapy as metastasis-directed therapy (MDT). Therefore, we developed a prognostic risk classification for biochemical relapse-free survival (bRFS) for patients after PSMA-PET-guided MDT after radical prostatectomy.

Methods: We analyzed 292 patients with local recurrence (LR) and/or pelvic lymph node (LN) lesions and/or up to five distant LN, bone (BM), or visceral metastases (VM) detected with [Ga]PSMA-PET imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04760-8DOI Listing

The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.

BJU Int 2020 Mar 16. Epub 2020 Mar 16.

Department of Surgery, University of Melbourne and Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Australia.

Objective: To review the ongoing randomised trials of cytoreductive prostatectomy (CRP) in de novo hormone-sensitive metastatic prostate cancer (HSPC) in order to identify their goals and assess their strengths and weaknesses.

Methods: PubMed, MEDLINE and clinical trials websites searches were performed to identify currently ongoing trials of CRP in de novo HSPC.

Results: Nine randomised clinical trials in CRP were identified and included: Southwest Oncology Group (SWOG) 1802, Surgery in Metastatic Carcinoma of Prostate (SIMCAP), Adjuvant Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (IP2-ATLANTA), Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone (TRoMbone), Impact of Radical Prostatectomy as Primary Treatment in Patients with Prostate Cancer with Limited Bone Metastases (g-RAMPP), Cytoreductive Prostatectomy vs Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial (LoMP II), Androgen-Deprivation Therapy or Androgen-Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) (FUSCC-OMPCa), and the Testing Radical Prostatectomy in Chinese Men with Prostate Cancer and oligoMetastases to the Bone study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.15055DOI Listing
March 2020
3.533 Impact Factor

Male axillary accessory breast cancer: A case report.

Medicine (Baltimore) 2020 Mar;99(11):e19506

General Surgery, Qingdao West Coast New Area Central Hospital, Qingdao, China.

Rationale: Accessory breast cancer is extremely rare among all cancerous diseases, especially in male patients. There were only few male axillary accessory breast cancer cases that have been reported in scientific literatures so far. Hereby, we would like to discuss a case of male axillary accessory breast cancer found in our hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019506DOI Listing

Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with Lu-PSMA-617.

EJNMMI Res 2020 Mar 6;10(1):18. Epub 2020 Mar 6.

Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands.

Background: Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in most patients. Five to 15% of patients become RAI refractory and need alternative therapy; however, treatment options are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-020-0610-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060303PMC

Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL).

BMJ Open 2020 Feb 28;10(2):e034623. Epub 2020 Feb 28.

Division of Uro-Oncology, Tata Memorial Centre, Mumbai, India.

Introduction: There has been an interest in studying the efficacy of extreme hypofractionation in low and intermediate risk prostate cancer utilising the low alpha/beta ratio of prostate. Its role in high-risk and node-positive prostate cancer, however, is unknown. We hypothesise that a five-fraction schedule of extreme hypofractionation will be non-inferior to a moderately hypofractionated regimen over 5 weeks in efficacy and will have acceptable toxicity and quality of life while reducing the cost implications during treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2019-034623DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050316PMC
February 2020
2.063 Impact Factor

Tumour metabolism and its unique properties in prostate adenocarcinoma.

Nat Rev Urol 2020 04 28;17(4):214-231. Epub 2020 Feb 28.

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.

Anabolic metabolism mediated by aberrant growth factor signalling fuels tumour growth and progression. The first biochemical descriptions of the altered metabolic nature of solid tumours were reported by Otto Warburg almost a century ago. Now, the study of tumour metabolism is being redefined by the development of new molecular tools, tumour modelling systems and precise instrumentation together with important advances in genetics, cell biology and spectroscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-020-0288-xDOI Listing

Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study.

Theranostics 2020 12;10(5):2273-2283. Epub 2020 Jan 12.

Department of Medical Oncology, Radboud university medical center, Nijmegen, the Netherlands.

: Treatment options for recurrent and/or metastatic (R/M) adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC), major subtypes of salivary gland cancer, are limited. Both tumors often show overexpression of prostate-specific membrane antigen (PSMA). In prostate cancer, PSMA-ligands labeled with Ga or Lu are used for imaging and therapy, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.38501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019174PMC
January 2020

Development of a high affinity Anticalin directed against human CD98hc for theranostic applications.

Theranostics 2020 12;10(5):2172-2187. Epub 2020 Jan 12.

Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising, Germany.

Enhanced amino acid supply and dysregulated integrin signaling constitute two hallmarks of cancer and are pivotal for metastatic transformation of cells. In line with its function at the crossroads of both processes, overexpression of CD98hc is clinically observed in various cancer malignancies, thus rendering it a promising tumor target. : We describe the development of Anticalin proteins based on the lipocalin 2 (Lcn2) scaffold against the human CD98hc ectodomain (hCD98hcED) using directed evolution and protein design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.38968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019167PMC
January 2020

Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report.

Medicine (Baltimore) 2020 Feb;99(8):e18889

APAC Biotech Pvt Ltd, Gurgaon, Haryana, India.

Rationale: Prostate cancer along with colorectal and lung cancers accounts for 42% of cancer cases in men globally. It is the first cancer indication for which the use of active immunotherapy, Sipuleucel-T (Provenge) was granted by the FDA in 2010. This study presents a case of prostate carcinoma and the tumour remission observed after administration of a personalised Dendritic cell vaccine (APCEDEN). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000018889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034657PMC
February 2020
5.723 Impact Factor

Tumor-to-Tumor Metastasis: Prostate Carcinoma Metastatic to Soft Tissue Sarcoma, a Previously Unreported Event.

Int J Surg Pathol 2020 Apr 6;28(2):196-199. Epub 2019 Sep 6.

University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Tumor-to-tumor metastasis is an unusual phenomenon wherein one distinct malignancy is present within the substance of another independent tumor. This event is rare, difficult to detect with imaging, and, due to conflicting terminology in the literature, can be challenging to classify. This article reports the first documented case of tumor-to-tumor metastasis involving prostatic adenocarcinoma and myxoid liposarcoma, reviews the available literature for carcinoma metastatic to sarcoma, and discusses the current situation within the context of the established criteria for the classification of combination tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1066896919872805DOI Listing
April 2020
0.961 Impact Factor

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.

J Exp Clin Cancer Res 2020 Feb 10;39(1):33. Epub 2020 Feb 10.

Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Level 6, 2775-Laurel St, Vancouver, BC, V5Z 1M9, Canada.

Background: Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment. Unfortunately, TKI resistance eventually develops, and the underlying molecular mechanism is not well understood.

Methods: RCC cell-line with metastatic clear-cell histology (Caki-1), and patient samples were analysed to identify the role of Y-box binding protein 1 (YB-1) and ATP-binding cassette sub-family B member 1 (ABCB-1) in acquired sunitinib-resistance development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-020-1527-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011538PMC
February 2020

Tumour functional imaging by PET.

Biochim Biophys Acta Mol Basis Dis 2020 Jun 5;1866(6):165717. Epub 2020 Feb 5.

Biophysics Institute, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; Clinical Academic Center of Coimbra, 3004-561 Coimbra, Portugal; Coimbra Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; CNC.IBILI Consortium/Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal. Electronic address:

Carcinogenesis is a complex multistep process, characterized by changes at different levels, both genetic and epigenetic, which alter cell metabolism. Positron emission tomography (PET) is a very sensitive image modality that allows to evaluate oncometabolism. PET functionalities are immense, since by labelling a molecule that specifically intervenes in a biochemical regulatory pathway of interest with a positron-emitting radionuclide, we can easily image that pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbadis.2020.165717DOI Listing

The role of T2-weighted images in assessing the grade of extraprostatic extension of the prostate carcinoma.

Abdom Radiol (NY) 2020 Jan 30. Epub 2020 Jan 30.

Department of Radiology, Istanbul Faculty of Medicine, Istanbul University, Capa, Fatih, 34093, Istanbul, Turkey.

Purpose: Extraprostatic extension (EPE) is an unfavorable prognostic factor and the grade of EPE is also shown to be correlated with the prognosis of prostate cancer. The current study assessed the value of prostate magnetic resonance imaging (MRI) in measuring the radial distance (RD) of EPE and the role of T2 WI signs in predicting the grade of EPE.

Materials And Methods: A total of 110 patients who underwent prostate MRI before radical prostatectomy are enrolled in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02419-4DOI Listing
January 2020

Primary Hepatocellular Carcinoma With Intense 68Ga-PSMA Uptake But Slight 18F-FDG Uptake on PET/CT Imaging.

Clin Nucl Med 2020 Mar;45(3):e176-e177

Department of Nuclear Medicine, Neolife Medical Center, Istanbul, Turkey.

Ga-PSMA PET/CT imaging is an emerging imaging modality in prostate cancer. PSMA expression is also reported for nonprostate malignancies, including primary hepatocellular carcinoma. Herein, we present a case of a 74-year-ald man with recently diagnosed hepatocellular carcinoma who was referred for F-FDG PET/CT imaging for initial staging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002922DOI Listing

68Ga-Prostate-Specific Membrane Antigen Uptake in Cerebral Tuberculosis.

Clin Nucl Med 2020 Mar;45(3):238-240

From the Department of Nuclear medicine and PET, Nepean Hospital, Kingswood.

A 71-year-old man with a history of high-risk prostate adenocarcinoma (Gleason score 4 + 5 = 9) treated with brachytherapy in 2016 was referred for a Ga-prostate-specific membrane antigen (PSMA)-HBED-CC PET/CT scan for suspected cancer recurrence on a background of slowly rising serum prostate-specific antigen (0.95 ng/mL; reference, <0.2 ng/mL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002910DOI Listing

99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?

Clin Nucl Med 2020 Mar;45(3):e148-e150

From the Departments of Nuclear Medicine.

We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences. More than 10 years after the diagnosis, follow-up Tc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002908DOI Listing

An exceptional case report of disseminated cryptococcosis in a hitherto immunocompetent patient.

Rev Inst Med Trop Sao Paulo 2020 17;62:e3. Epub 2020 Jan 17.

University of Belgrade, Faculty of Medicine, Belgrade, Serbia.

Cryptococcosis is an opportunistic fungal infection causes significant disease predominantly in immunocompromised patients. Here we present an excepcional case of disseminated cryptococcosis with pulmonary and cerebral involvement in an immunocompetent patient with no apparent predisposing factors at the time of hospital admission. We described a case of an apparently immunocompetent 66-years old man admitted to hospital with a one-month history of cough, fever and vertigo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1678-9946202062003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968789PMC
February 2020

[NON-SPECIFIC GRANULOMATOUS PROSTATITIS: A CASE REPORT].

Nihon Hinyokika Gakkai Zasshi 2019 ;110(1):65-69

Department of Urology, Yokosuka-Kyosai Hospital.

We report non-specific granulomatous prostatitis in a 58-year-old man who visited a Urology clinic with fever and dysuria. Digital rectal examination revealed prostatic tenderness, and laboratory examination of the urinary sediment revealed pyuria. Thus, he was diagnosed with acute bacterial prostatitis and treated with antibiotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5980/jpnjurol.110.65DOI Listing
January 2019

[The Value of MRI Texture Analysis in Identifying Intraductal Carcinoma of the Prostate Gland].

Sichuan Da Xue Xue Bao Yi Xue Ban 2020 Jan;51(1):42-48

Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China.

Objective: To explore the value of a radiomics approach based on MRI texture analysis (TA) in identifying intraductal carcinoma of the prostate gland (IDCP).

Methods: MRI images of 56 patients with pathological proven prostate cancer were analyzed retrospectively, including 31 patients with pure prostate adenocarcinoma and 25 patients with IDCP component in the prostate adenocarcinoma lesions. After imaging features of lesions were analyzed, then enhanced arterial and venous phase images were imported into Omni-Kinetics software for the extraction the TA features of region of interests' lesion according to the T2-weighted imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12182/20200160101DOI Listing
January 2020

Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Nat Rev Urol 2020 02 14;17(2):107-118. Epub 2020 Jan 14.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly being established as arguably the leading contemporary imaging modality in the management of prostate cancer. Outside of its conventional use in the de novo staging of localized disease and detection of biochemical recurrence, additional applications for the use of PSMA PET are emerging. Uptake of PSMA tracers in other genitourinary malignancies, particularly renal cell carcinoma, has led to new fields of investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0272-5DOI Listing
February 2020

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.

Proc Natl Acad Sci U S A 2020 01 13;117(4):2032-2042. Epub 2020 Jan 13.

Department of Radiology, Stanford University, Stanford, CA 94304;

Resistance to androgen deprivation therapy, or castration-resistant prostate cancer (CRPC), is often accompanied by metastasis and is currently the ultimate cause of prostate cancer-associated deaths in men. Recently, secondary hormonal therapies have led to an increase of neuroendocrine prostate cancer (NEPC), a highly aggressive variant of CRPC. Here, we identify that high levels of cell surface receptor Trop2 are predictive of recurrence of localized prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1905384117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994991PMC
January 2020

Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?

Int J Radiat Oncol Biol Phys 2020 02;106(2):236-237

Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.07.002DOI Listing
February 2020